A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, ...

There are about 80,000 new cases of bladder cancer every year in the US alone. About one-third of cases are diagnosed at late ...

Research and development expenses for the third quarter of 2024 increased to $8.1 million from $6.2 million for the prior ...

Though they may seem like something from the future, these five cancer vaccines are available now. Here are details about who ...

Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today ...

The 2024 South Central AUA annual meeting included the Sushil Lacy manuscript competition, featuring a presentation by Dr. Amanda Myers discussing the elucidation of response rates to additional BCG ...

Patients were further queried to identify those who received adequate BCG induction (defined as ≥ 5 weekly instillations). They then summarized the distribution of this group and the treatments ...

“We see a pattern of growing investor demand in the tokenized funds space,” said David Chan, managing director and partner at BCG. The paper, jointly produced with Aptos Labs and ...

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been discontinued.